Lialda® / Mezavant® / Mesavancol® is a proprietary formulation for targeting the release of high concentrations of mesalazine (5-aminosalicyd acid or 5-ASA), based on the MMX® technology, to the colon. Lialda® / Mezavant® is indicated for the induction and maintenance of clinical and endoscopic remission in patients with active, mild-to-moderate Ulcerative Colitis and is, to Cosmo's knowledge, the first available once daily mesalazine treatment.
Lialda® / Mezavant® / Mesavancol® is an oral tablet formulation able to deliver mesalazine directly into the lumen of the colon; the specific pharmaceutical product dissolution profile increases the colonic specific disposition of mesalazine, reduces the pre-colonic systematic absorption and allows the product to be especially effective for the treatment of both proximal and distal Ulcerative Colitis.
Through the application of the MMX® technology, patients taking mesalazine in non-acute phases will have to take about two tablets a day and during acute phases of Ulcerative Colitis about three to four tablets a day. The expected reduction in the number of tablets to be taken in comparison to standard oral administration of mesalazine facilitates increased patient compliance.